Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Forte Biosciences, Inc.NASDAQ: FBRX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $22.14M (cash outflow) rose 41.4% year over year, behind the +73.5% change in trailing-twelve-month net income. Sequentially, it fell 10.7% from the prior quarter. Over 3 fiscal years it compounded at +71.0% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$604.31M (+771.1%) for the fiscal year ending Dec 2026, a step up from the +95.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$22.14M-10.7% QoQ
- Last fiscal yearDec 2025
- -$69.38M+95.5% YoY
- LTMMar 2026
- -$75.86M+73.5% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (69.38M) USD
- Year-over-year change
- -95.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (69.38M) | -95.5% |
| FY2024 | 2024-12-31 | (35.48M) | -12.7% |
| FY2023 | 2023-12-31 | (31.48M) | -126.8% |
| FY2022 | 2022-12-31 | (13.88M) | +36.1% |
| FY2021 | 2021-12-31 | (21.71M) | — |
Net Income vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +73.5% is the highest of 10, against a peer median of -10.2%.
- Over three fiscal years its annual growth of +71.0% compares with a peer median of +4.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $129.91M USD | -26.1% | -21.5% | 2056.8% | |
| LTM Mar 2026 | $125.39M USD | +1.6% | +2.3% | 680.8% | |
| LTM Mar 2026 | $99.93M USD | -10.2% | -2.9% | — | |
| LTM Mar 2026 | $84.53M USD | +68.1% | +22.9% | — | |
| LTM Mar 2026 | $77.22M USD | -24.4% | +9.1% | — | |
| LTM Mar 2026 | $75.86M USD | +73.5% | +71.0% | — | |
| LTM Mar 2026 | CHF 64.16M CHF | +7.8% | — | — | |
| LTM Mar 2026 | $44.76M USD | -8.4% | +5.8% | 8526.1% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $40.19M USD | -21.6% | +11.9% | — |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $21.54M USD | -14.9% | +3.3% | — |
| Peer median (excluding FBRX) | — | -10.2% | +4.6% | 2056.8% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (21.71M) | (13.88M) | (31.48M) | (35.48M) | (69.38M) |
| Depreciation & Amortization | 36K | 0 | 9K | 39K | 64K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 1.04M |
| Stock-Based Compensation | 4.21M | 4.02M | 3.28M | 3.1M | 6.26M |
| Change in Working Capital | 720K | 1.68M | (392K) | 1.76M | 11.37M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (294K) | 207K | 271K | 3.02M | 5.54M |
| Other Working Capital | 1.01M | 1.47M | (663K) | (1.26M) | 5.83M |
| Other Non-Cash Items | 61K | 0 | (131K) | (158K) | (237K) |
| Operating Cash Flow | (16.68M) | (8.19M) | (28.71M) | (30.75M) | (50.88M) |
| Capital Expenditures | 0 | 0 | (88K) | (37K) | (116K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (9.97M) | (35.96M) | 0 |
| Sales of Investments | 0 | 0 | 10.1M | 0 | 36.35M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 47K | (35.99M) | 36.23M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 62K | 7.23M | 24.74M | 53M | 76.83M |
| Common Stock Repurchased | 0 | 0 | 0 | (1K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (106K) | 12K | (44K) | (1.14M) | (7.47M) |
| Financing Cash Flow | (44K) | 7.24M | 24.68M | 51.86M | 69.36M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (16.72M) | (944K) | (3.98M) | (14.88M) | 54.71M |
| Free Cash Flow | (16.68M) | (8.19M) | (28.79M) | (30.78M) | (51M) |
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.